Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094496 · ClinicalTrials.gov registry record · Phase 2
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
A Phase 2 study, sponsored by Celldex Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT01094496 is a Phase 2 study that was terminated before completion, run by Celldex Therapeutics. The registered enrollment target is 3 participants.
The verdict
NCT01094496, a Phase 2 study, was terminated before completion, sponsored by Celldex Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The major purpose of this study is to examine the anti-tumor activity of the CDX-1307 vaccine regimen when it is given before and after bladder cancer surgery. The study will also provide information about the safety of the vaccine regimen when given in combination with chemotherapy, and how it affects the immune systems.
Interventions
- DRUG Chemotherapy
- BIOLOGICAL CDX-1307 Vaccine Regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01094496
The ClinicalTrials.gov registry entry for NCT01094496 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chemotherapy is the first listed.
NCT01094496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01094496 about?
NCT01094496 is a clinical study titled "A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)". The major purpose of this study is to examine the anti-tumor activity of the CDX-1307 vaccine regimen when it is given before and after bladder cancer surgery. The study will also provide information about the safety of the vaccine regimen when given in combination with chemotherapy, and how it affe...
What is the current status of trial NCT01094496?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2010-04. Estimated completion is 2011-07.
What interventions are being tested in trial NCT01094496?
The interventions under investigation include: Chemotherapy (DRUG), CDX-1307 Vaccine Regimen (BIOLOGICAL).
Who is sponsoring clinical trial NCT01094496?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.